Professor Nadia Harbeck
Professor Harbeck, Head of the Breast Center at the University of Munich [LMU] in Germany, provides her expert insight into key data presented at ASCO 2018 and what they may mean for optimizing clinical outcomes for patients with advanced breast cancer.
Key topics include:
The place of CDK4/6 inhibitors in relation to endocrine therapy in the treatment sequence for HR+/HER2- advanced breast cancer.
Whether the differing safety profiles of CDK4/6 inhibitors are important when making decisions regarding patient management.
The current challenges for conserving the quality of life of patients with HR+/HER2- advanced breast cancer, compared with managing disease progression.
Whether a broader choice of treatment options may be available in the near future for advanced breast cancer based on the wealth of early phase studies presented at ASCO 2018.
Specific data for advanced breast cancer that were of particular interest for Professor Harbeck at ASCO 2018, and any implications of these for the management of patients from a national and regional perspective in Germany.
Clinical Expert Video Series
Watch internationally renowned breast cancer clinicians discussing the latest data from the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5, and what they may mean for clinical practice.
Nadia Harbeck, MD, PhD, is Head of the Breast Center and holds the Chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany. She obtained her specialist degree (OB&GYN) at the Technical University of Munich (TUM) and her medical degree from the University of Munich. From 2005 to 2009, she was an Assistant Professor and Head of Conservative Senology at TUM and from 2009 to 2011, she was Head of the Breast Center at the University of Cologne, Germany.
Professor Harbeck is a member of the expert panel issuing the yearly updated evidence-based AGO Guidelines for breast cancer therapy in Germany (
www.ago-online.de). She is Scientific Director of the West German Study Group ( www.wsg-online.com). From 2009 to 2015, she served on the executive board of the EORTC as the Chair of the translational research division. Professor Harbeck is Principal Investigator or Steering Committee member of numerous national and international clinical breast cancer trials, particularly with novel targeted compounds. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumours. She has a strong interest in eHealth and is a co-developer of CANKADO, an international digital patient diary ( www.cankado.com).
Professor Harbeck has authored more than 450 papers in peer-reviewed journals (cumulative impact factor > 2000; h-index 67) and is coordinating Editor-in-Chief of Breast Care (Karger Publishers). For her clinical translational research, she has received numerous awards, including the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2008 EBCC Award (Emmanuel van der Schueren Lecture), the 2002 AGO Schmidt-Matthiesen Award, a 2001 AACR Award, and the 2001 ASCO Fellowship Merit Award for the highest-ranking abstract submitted. She is a panel member of several international breast cancer consensus conferences, such as for advanced breast cancer (ABC), breast cancer in young women (BCY), and early breast cancer (St Gallen).
Disclosures: Honoraria for lectures and consulting from Lilly, Novartis and Pfizer.
ASCO 2018 Highlights